摘要
目的:比较多沙唑嗪联合托特罗定与坦索罗辛联合托特罗定治疗良性前列腺增生(BPH)下尿路症状(LUTS)的尿流动力学变化的研究。方法:选取诊断明确的BPH患者50例,采用随机非双盲方法平均分为A、B两组,A组患者服用多沙唑嗪联合酒石酸托特罗定缓释剂、B组患者服用坦索罗辛联合酒石酸托特罗定缓释剂联合治疗12周,于治疗前后对潴尿期与排尿期的相关尿流动力学指标,如最大尿流率(Qmax)、膀胱剩余尿量、最大膀胱容量、排尿开始时膀胱压、膀胱顺应性等进行比较。结果:两组在治疗前的各项指标无统计学意义。服药治疗12周后,两组Qmax、排尿开始时膀胱压、膀胱顺应性均较治疗前有明显改善。而剩余尿量和最大膀胱容量较治疗前无明显变化。治疗后两组间比较,A组Qmax、排尿开始时膀胱压、膀胱顺应性均优于B组(P<0.05),而两治疗组之间的剩余尿量及最大膀胱容量差异无统计学意义(P>0.05)。结论:α受体阻滞剂联合M受体阻滞剂治疗BPH能明显提高Qmax,降低排尿开始时膀胱压力,改善膀胱顺应性,且多沙唑嗪联合应用M受体阻滞剂优于坦索罗辛联合应用M受体阻滞剂。
Objective： To compare urodynamic changes of different alpha-receptor blockers （doxazosin and ta- msulosin） combined with M-receptor blocker （tolterodine tartrate） for treatment of lower urinary tract symptoms （LUTS） in patients with BPH. Method： Fifty patients diagnosed with BPH were randomly divided into two groups with open labeled： group A treated with doxazosin and tolterodine tartrate; group 13 treated with tamsulo- sin and tolterodine tartrate. The effects of urodynamics were evaluated with maximum flow rate （ Q max）, residual bladder volume, maximum cystometric capacity （MC13C）, intravesical pressure （Pves）, bladder compliance （13C）, before and after 12 weeks treatment. Result： All parameters showed no significant differences before treatment be- tween two groups. After 12 weeks treatment, Q max, Pves and 13C improved obviously in both groups, while the results of residual bladder volume and MCBC were similar. The indexes Q Pves, and 13C of group A were su- perior to group B （ P〈0.05）, while residual bladder volume and MCBC did not show any differences （ P〉 0.05）. Conclusion： Administration of alpha-receptor blockers combined with M-receptor blocker in patients with LUTS associated with BPH can improve Q max, BC and Pres. Furthermore, doxazosin is superior to tamsulosin combined with tolterodine tartrate in treatment of LUTS associated with BPH.
出处
《临床泌尿外科杂志》
2014年第4期304-306,310,共4页
Journal of Clinical Urology
基金
辉瑞IIR项目(编号WS1877452)
